Berylliosis is an environmental chronic inflammatory disorder of the lung caused by inhalation of beryllium dusts, characterized by the accumulation of CD4+ T cells and macrophages in the lower respiratory tract.Beryllium presentation to CD4( +) T cells from patients with berylliosis results in T cell activation, and these Be-specific CD4( +) T cells undergo clonal proliferation and Thl-type cytokine production such as interleukin-2, interferon-gamma and tumor necrosis factor-alpha. In exposed workers, genetic susceptibility to this granulomatous disorder is associated with major histocompatibility gene and the TNF-a gene. The HLA·DP glutamic 69 residue was shown to be the MHC genetic marker associated with disease susceptibility; furthermore the TNF-a TNFA-308*2 allele was found to be independently associated with HLA·DP Glu69 in the determination of berylliosis risk.
Hypersensitivity disorders of the lower respiratory tract: the berylliosis model
The lung is constantly burdened by an extraordinary number of airborne particles contained in the seven to ten thousands liters of inhaled air daily. Particles, chemical agents and antigens are cleared by the mucociliary escalator or destroyed by the cells of the lung immune system, they do cause though a constant state of activation of the lung-compartmentalized immune effector cells (1) and in a fraction of the exposed individuals exaggerated reactions leading to tissue damage and lung dysfunction. A host of inhaled antigens including metals such as beryllium (2) , zirconium (3) (4) (5) , titanium (6) and aluminium (7) , organic dusts (8, 9) and chemicals such as isocyanates (10) can cause hypersensitivity lung reactions.
Berylliosis is the best understood model of lung hypersensitivity reaction. The diagnosis of berylliosis include: a positive history of exposure to beryllium or demonstration of beryllium in tissue specimens, a chest X-radiograph showing diffuse reticulo-nodular infiltrates and or hilar adenopathy, a lung biopsy showing non-caseating granulomas and a positive lymphocyte reaction to beryllium salts. Current immunologic testing for beryllium sensitization use in vitro radiometric beryllium-stimulated proliferation tests of blood and lung T-cells (blood Be-LPT and lung Be-LPT). The test shows 38% sensitivity and 97% specificity (11) .
Current concepts are that granulomatous and autoimmune reactions are maintained by the activation of type 1 T-helper CD4 T-cells i.e., interleukin (IL)-12 induced T-cells capable of releasing macrophage activating factors such as interferon (IFN)-"'( and tumor necrosis factor (TNF)a. Consistent with this concept, lung T-cells respond to beryllium with the release ofTH 1type cytokines such as IL-2, the migration inhibition factor (MIF), IFN-"'( and TNF-cx (12) (13) (14) (15) .
Consistent with these concepts berylliosis has been associated both with a major histocompatibility gene (MHC), i.e., the genes that drive the T-cell response by selecting the antigenic determinants to which the individuals can mount a specific Tcell reaction and with a cytokine gene i.e., the TNF-a gene.
The HLA-DP glutamic 69 residue was shown to be the MHC genetic marker associated with disease susceptibility in a retrospective study of berylliosis cases (16) . In this study, the evaluation of MHC class II genes in 33 CBD cases and 44 controls showed a negative association with HLA-DPB 1*040 1 (P<O.OO 1) and a positive association with HLA-DPB 1*0201 (P<0.05) alleles, which differ at residues 36, 55, 56, and 69 of the b chain. Among berylliosis cases, 97% expressed the HLA-DPB 1*020 I-associated glutamic acid (non cases 30%; P<O.OOI) at residue 69, thus indicating this polymorphic residue as the genetic marker of disease susceptibility (16) .
The TNF-a TNFA-308*2 allele was found to be independently associated with HLA-DP Glu69 in the determination of berylliosis risk in a nested case control study of a population of639 individuals of a beryllium manufacturing plant. In this study, the frequency of the TNFA-308*2 allele was significantly increased among individuals with beryllium hypersensitivity i.e., among individuals with a positive beryllium lymphocyte proliferation test (BeLPT) (OR 7.8, corrected p<O.OOO 1, 95%CI 3.2-19.1) compared to BeLPT-negative controls (17) .
Finally, berilliosis incidence is determined by the interaction between exposure dose (and type) and the exposed individual's genetic background. Kreiss and coworkers, using job history analysis and historic exposure assessment have shown that disease rates vary in fact with the exposure type and intensity, from less than 1% in the less exposed workers and clerical workers to more than 10% in the more exposed machinists (18) (19) (20) (21) . In a collaborative study employing industrial hygiene (20) and genetic epidemiology tools on the same cohort of beryllium ceramics workers, Richeldi and coworkers (22) were able to show that the expression of the HLA-DP glutamic 69 residue, the genetic marker associated with susceptibility to berylliosis (16) , and the exposure types and levels acted as independent risk factors. Importantly, the carriage of the genetic factor had an effect upon exposure in the determination of risk, leading to a lO-fold increase in risk for those carrying the marker who where exposed in higher risk jobs (22) .
Mechanisms of Be recognition by specific Tcells.
Lombardi et al. generated T-cell clones from three patients with berylliosis, all expressing the susceptibility marker HLA-DPGlu 69 in one or both oftheir DPI3 chains (23) . The T cell lines and clones were generated by culturing PBMC with BeS0 4x4H20, as previously described (1) and their reactivity to different doses of Be investigated using homozygous B-LCLs from the Xth IHW as A Fig A Proliferation
antigen presenting cells (APC). All the T cell clones tested responded to Be only when it was presented by B-LCLs expressing HLA-DPB1*0201.
No response was detected to DPB 1*020l-negative B-LCLs expressing the HLA-DR of the patients, thus indicating the HLA-DP molecules the immune response gene of the T-cell response to beryllium. Further, all the T cell clones tested were completely inhibited by the presence of anti-HLA-DP mAb, in contrast, no inhibition was observed with the mAb against HLA-DQ molecules. In all the experiments performed the presence of the anti-HLA-DR mAb (L243) consistently led to 30 to 50% inhibition. In this regard, Lombardi et al (23) showed that the effect of HLA-DR antibodies upon Be-specific T-cell clones was due to cell death of the B-LCL presenting Be induced by the cross-linking ofthe MHC-class II molecules (24) , that lead to apoptosis. In this study, they showed that after 3 hours from the addition of anti-DR (L243) mAb more than 40% the antigen presenting cells underwent cell death, while the anti-DP mAb, which inhibited T cell proliferation, did not cause any cell death compared to untreated cells. Importantly, Lombardi and colleagues showed that when they tested the response of Be-specific T-cell clones on antigen presenting B-LCL(s) expressing either HLA-DPBl *0201 or HLA-DPBl *0402, that shared the same DPa chain and differ only at position 69 in the 13 chain, all the Bespecific T-cell clones obtained responded only to the B-LCL with Glu at residue 69. Altogether these data indicated HLA-DP as the restriction element for Be-specific T-cells and showed that the presence of Glu at residue 69 was essential for the reactivity of T-cell clones to Be, thereby indicating the genetic maker HLA-DP Glu 69 as the specific immune response gene of the response to beryllium.
Consistent with the ex vivo data obtained with bronchoalveolar lavage cells from berylliosis patients (15) Lombardi and colleagues showed also that all the Be-specific T cell clones tested produced IFN -"( and little or no IL-4. These results suggest that the Be-specific T-cell clones raised from PBMC of CBD patients are likely to be derived from pathogenic T-cells. Further, they showed that PBMC derived T-cell clones displayed a T-cell receptor gene beta chain variable region (CDR3) sequence identical, besides a conservative substitution (Val-Leu) at position 92, to a sequence previously described by Fontenot et al. as present at high frequency in the BAL of a patient with CBD (25) . Moreover, the T cell clone analysed used the same V-alpha chain reported in the same study (23, 25) .
Role of HLA-DP in beryllium binding and presentation
Although the immune response gene of the reaction to beryllium has been clearly identified by the above studies through the identification of HLA-DP Glu69 both as the MHC restriction element of the T-cell reaction to beryllium and the disease associated susceptibility marker, nor the nature of the "Be antigen" responsible for T-cell activation nor the mechanism of interaction between this antigen and the MHC molecules have been definitely characterized.
In order to address this question, we evaluated the interaction between beryllium and the HLA-DP Glu69 molecules using engineered HLA-DP2 soluble molecules carrying a glutamate residue in position 69 of the~chain (HLA-DP2) in comparison to HLA-DP2 soluble molecules carrying a lysine in position 69 (HLA-DP2Lys69) (26) . In this study HLA-DP2 and HLA-DP2Lys69 molecules were expressed in insect cells and purified to homogeneity to generate soluble, correctly folded HLA-DP molecules as assessed with the conformation sensitive MoAb HLA-DP B7121 in ELISA (Fig. 1) .
By using these molecules we analysed the interaction between HLA-DP molecules and Be both at pH 5.0, i.e., the pH mimicking the intracellular microenvironment in which peptides are loaded onto HLA-class II molecules and at pH 7.4 i.e., the pH mimicking the extracellular environment.
Since analysing the Be/HLA-DP by the ability of the metal to compete with the Class-II associated Invariant-chain peptide (CLIP), a peptide capable to bind to all MHC class II molecules, for the binding to HLA-DP molecules we were able to show that BeS0 4 (1-1000 /-LM) was capable of competing with the biotinilated-CLIP (50 _M) peptide for the binding to HLA-DPGlu69-positive soluble molecules, as BeS0 4 displaced biotin-CLIP from the HLA-DP2 (lC50% 4.5 mM of BeS0 4; IC50% 53 _M of non-biotinilated CLIP) but not from the HLA-DP2Lys69 molecule (IC50% 480 /-LM of BeSO4; IC50% 49 mM of non-biotinilated CLIP) (26) . Moreover, BeS0 4 was able to modify significantly the binding of the MoAb NFLD .M60, which recognizes an epitope in the HLA-DP peptide binding region, to HLA-DP2 molecule (OD 492 nm=195±37, in absence of Be OD492nm=432±84, p<0.02) but not to HLA-DP2Lys69 (OD492nm=321±31, in absence of Be OD492nm=342±77, p>0.05).
Although this data does not demonstrate that a beryllium/HLA-DP complex generated by the interaction of beryllium with the HLA-DP Glu 69 molecule both at pH 5.0 and 7.4 i.e., both in the intracellular and the extracellular environment of the lung, is the is the neo-antigen driving the immune reaction of berylliosis, it strongly argues for a direct interaction ofbery Ilium with the genetic susceptibility marker/immune response gene molecule HLA-DP Glu 69, in exposed individuals (Fig.2) .
Role ofthe cytokine gene TNF-a in the generation of beryllium hypersensitivity
We have recently demonstrated that the TNFA2 allele of the cytokine gene TNF-a, which is expressed at exaggerated levels by lung and blood mononuclear cells from berylliosis patients in response to Be (14, 15) , is also associated with susceptibility to beryllium hypersensitivity and positively interacts with the HLA-DPGlu69 marker to increase berylliosis risk (17) .
Since the THI cytokines IFN-"( and TNF-a, both hyper-expressed by berylliosis patient mononuclear cells in response to Be (15) playa central role in granulomatous reactions (27) , it was critical to the understanding of the pathogenesis of beryllium hypersensitivity to assess whether the expression of TNF-a is the consequence of Be-specific CD4 T-cell activation or instead is a related but independent event, as the genetic association finding may suggest.
In order to address this question a cell activation assay where PBMCs were stimulated with Be using an anti-HLA-DP monoclonal antibody to separate the response to the metal of Be-specific HLA-DPGlu69-restricted THI CD4+ T-cells from that of the mononuclear phagocytes, we evaluated PBMCs from ten individuals with berylliosis, all carrying glutamate 69 positive HLA-DP alleles, and from five healthy controls as the source of both T-cells and mononuclear phagocytes.
In this study, PBMCs obtained from berylliosis patients showed a proliferative response to BeS0 4 (figure 3, panel A). In all of them the anti-HLA-DP specific MoAb induced a marked inhibition of Be-stimulated proliferation (88±16%) that was significantly greater than that obtained with MoAbs against HLA-DR (29±38%) HLA-DQ (2±2%) class-I MHC (1±2%) and the M. tuberculosis 19kDaspecific protein (O±l %; p<0.05 all comparisons with anti-HLA-DP) ( figure 3, panel A) . PBMCs from Be non-exposed healthy subjects did not proliferate in response to BeS0 4 • In addition, the PBMCs from berylliosis patients released IFN-g in response to Be stimulation (figure 3, panel B). Strikingly, the release of this cytokine was strongly blocked by the anti-HLA-DP MoAb (77±16%) but not by the other MoAbs used (anti-HLA-DR, 14±1O%; anti-HLA-DQ, 1±2%, anti-class-I, 1+1%, anti-M. tuberculosis 19 kDa-specific protein, 0±1 %; p<0.05 all comparisons with anti-HLA-DP) (Figure 3, panel  B) . Consistently with the proliferation data, none of the five healthy non Be-exposed controls released IFN-oy in response to BeS0 4 • With regard to the induction of the expression of the THI cytokine TNF-a by beryllium stimulation, PBMCs from all of the nine berylliosis patients tested released TNF-a in response to beryllium (figure 3, panel C), as they did in response to PHA. In contrast toIFN-oythough, the release of TNF-a was not blocked by the anti-HLA-DP specific monoclonal antibody (figure 3, panel C).
Similarly to berylliosis patients, PBMCs obtained from 4 out of 5 non Be-exposed healthy subjects released TNF-a ain response to BeS0 4[195 As for the mononuclear cells from the bery lliosis patients, anti-HLA class II monoclonal antibodies had no effect on the cytokine release from control mononuclear cells.
In granulomatous disorders, such as tuberculosis, leprosy and sarcoidosis, IFN-oy producing THI Tcells dominate the disease immune response (28) (29) (30) (31) . In the context that HLA-DP glutamate 69positive molecules are capable of directly binding beryllium (26) may suggest that Be presentation in the presence of this molecule may itself drive the THI response as described in animal models where the TH 1 or TH2 polarization of the immune response is dictated by a specific MHC/peptide combination (32) .
The data would though suggest that the two cytokines here evaluated, IFN-oy and TNF-a play different roles in the generation of beryllium hypersensitivity.
TNF-a is, together with IFN-oy the dominant cytokine produced in the reaction to Be by mononuclear cells from berylliosis patients. Since TNF-a is primarily released by mononuclear phagocytes (33) , it is reasonable to ask whether cytokine production is driven by, or independent of, THI T-cell activation and IFN-oy release. The antibody blocking experiments in the study clearly show that Be-stimulated blood mononuclear phagocytes were able to release TNF-a independently ofHLA-DP restricted IFN-oy release. Moreover, the ability ofPBMCs of non Be-exposed healthy subjects to release TNF-a in response to Be salt strongly support this notion.
With the background of the observation that the TNFA2 and the HLA-DPGlu69 marker positively and independently interact in the determination of berylliosis risk (17) , the data bring further support to notion that the TNF-oy and the HLA-DP gene are immunogenetic independent factors of berylliosis that in their "functional" role may interact in the development of granulomatouos reaction induced by Be in the lung.
